The global Dupixent market was valued at USD 14.15 billion in 2024 and is projected to reach USD 27.58 billion by 2033, expanding at a CAGR of 7.70% from 2025 to 2033. This growth reflects a broader shift in the treatment of Type 2 inflammatory diseases from conventional therapies to targeted biologics.
Dupixent, co-developed by Sanofi and Regeneron, leverages a novel mechanism of action by inhibiting interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathways. The increasing prevalence of Type 2 inflammatory conditions—such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP)—continues to fuel market demand. Additionally, recent regulatory approvals for indications like bullous pemphigoid and eosinophilic esophagitis further expand the drug’s therapeutic reach.
With an estimated 200 million individuals suffering from atopic dermatitis and 300 million asthma patients globally in 2024, the need for safer and more effective treatment options has never been greater. Dupixent offers a superior safety and efficacy profile over traditional treatments such as corticosteroids, making it a preferred option in both adult and pediatric populations.
Ongoing clinical development efforts are expected to unlock new opportunities for market growth. Trials such as LIBERTY-CSU CUPID for chronic spontaneous urticaria and studies targeting allergic fungal rhinosinusitis aim to expand Dupixent’s use across additional inflammatory and immunologic indications. Pediatric approvals and studies, particularly in eosinophilic esophagitis, and the January 2024 approval for bullous pemphigoid, are expected to significantly broaden the eligible patient base and enhance long-term market penetration.
Key Market Insights:
- North America dominated the global Dupixent market with a 76.15% revenue share in 2024, driven by its robust healthcare infrastructure, early adoption of biologics, and supportive reimbursement frameworks.
- By distribution channel, hospital pharmacies held the largest market share at 53.94% in 2024, due to their critical role in administering Dupixent for severe conditions such as asthma and COPD, particularly in inpatient care settings.
Order a free sample PDF of the Dupixent Market Intelligence Study, published by Grand View Research.
Market Size & Forecast
- 2024 Market Size: USD 14.15 Billion
- 2033 Projected Market Size: USD 27.58 Billion
- CAGR (2025-2033): 7.70%
- North America: Largest market in 2024
- Asia Pacific: Fastest growing market
Key Companies & Market Share Insights
Sanofi and Regeneron jointly lead the Dupixent market through a strategic alliance that underpins both clinical innovation and global expansion. Their collaboration focuses on broadening the drug’s therapeutic reach, marked by recent FDA approvals for bullous pemphigoid and chronic spontaneous urticaria in 2025, supported by pivotal trials such as LIBERTY-CSU CUPID.
The partners continue to invest in real-world evidence and pediatric formulations, strengthening Dupixent’s market presence across key regions including North America, Europe, and Asia Pacific. In emerging markets such as Latin America and the Middle East & Africa, patient access programs and adaptive pricing strategies are being implemented to address affordability and improve accessibility.
Leveraging their combined regulatory expertise and distribution capabilities, Sanofi and Regeneron have accelerated market entry and availability across multiple geographies. Their partnership reinforces Dupixent’s leadership in the interleukin inhibitor segment, setting a benchmark for innovation in the treatment of Type 2 inflammatory diseases.
Key Players
- Sanofi
- Regeneron
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion
The Dupixent market is experiencing substantial growth, primarily fueled by the rising incidence of Type 2 inflammatory diseases and the drug's distinctive mechanism of action. North America currently holds a significant portion of the market, with atopic dermatitis being the leading indication, though other indications are showing rapid expansion. The market's upward trajectory is further supported by continuous research, strategic alliances between key developers, and recent regulatory clearances for new uses, which are broadening the drug's therapeutic reach. Furthermore, intellectual property protection in major markets is expected to help maintain this growth by mitigating immediate competition.
